Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04967664 · ClinicalTrials.gov registry record · Phase 3
Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery
A Phase 3 study of Post Surgical Neuropathic Pain, sponsored by Averitas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 409
- Enrollment target
- 20
- Study locations
NCT04967664 is a Phase 3 study of Post Surgical Neuropathic Pain that has completed, run by Averitas Pharma. The registered enrollment target is 409 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT04967664, a Phase 3 study of Post Surgical Neuropathic Pain, has completed, sponsored by Averitas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 409 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an interventional, Phase III, double-blind, randomized, controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of repeated topical application of Qutenza (capsaicin 8% topical system) versus low-dose capsaicin control (capsaicin 0.04% topical system) in subjects with moderate to severe postsurgical neuropathic pain (PSNP).
Conditions Studied
Interventions
- DRUG Qutenza (capsaicin) 8% topical system
- DRUG capsaicin 0.04% topical system
Study Locations (20)
Florida
- South Lake Pain Institute - Clermont
- University Clinical Research - DeLand Clinical Research Unit - DeLand
- Florida Research Center, Inc. - Miami
- Clinical Research of West Florida - Tampa
Kansas
- Neuroscience Research Center, LLC - Overland Park
- Kansas City Bone & Joint Clinic, P.A. - Overland Park
North Carolina
- Accellacare - Wilmington
- The Center for Clinical Research - Winston-Salem
Arizona
- Tucson Orthopaedic Institute - Tucson
California
- ILD Research Center - Vista
District of Columbia
- International Spine, Pain, and Performance Center - Washington D.C.
Georgia
- Drug Studies America - Marietta
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 409 participants |
| Start Date | 2021-07-13 |
| Est. Completion | 2025-08-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04967664
The ClinicalTrials.gov registry entry for NCT04967664 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 409 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Averitas Pharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post Surgical Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Qutenza (capsaicin) 8% topical system is the first listed.
NCT04967664 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, Kansas, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04967664 about?
NCT04967664 is a clinical study titled "Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery". This is an interventional, Phase III, double-blind, randomized, controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of repeated topical application of Qutenza (capsaicin 8% topical system) versus low-dose capsaicin control (capsaicin 0.04% topical system) in sub...
What is the current status of trial NCT04967664?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 409 participants. The study started on 2021-07-13. Estimated completion is 2025-08-28.
What conditions does trial NCT04967664 study?
This clinical trial studies the following conditions: Post Surgical Neuropathic Pain.
What interventions are being tested in trial NCT04967664?
The interventions under investigation include: Qutenza (capsaicin) 8% topical system (DRUG), capsaicin 0.04% topical system (DRUG).
Who is sponsoring clinical trial NCT04967664?
This trial is sponsored by Averitas Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04967664 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.